← All trials
NCT06831825
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 23, 2025
- Primary completion
- Dec 31, 2026
- Completion date
- Jun 30, 2027
- First posted
- Feb 18, 2025
- Last posted
- Apr 27, 2025
- Enrollment
- 24
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- YAP Therapeutics, Inc.Lead sponsor
- Texas Heart InstituteOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.